{
    "clinical_study": {
        "@rank": "112532", 
        "arm_group": [
            {
                "arm_group_label": "Indolent myeloma patient"
            }, 
            {
                "arm_group_label": "Symptomatic Myeloma patient"
            }
        ], 
        "brief_summary": {
            "textblock": "Whole body MRI with diffusion weighted imaging is a useful imaging tool\n\n        -  staging and diagnosis\n\n        -  therapy monitoring All patients will be scanned before and during treatment. The\n           findings on diffusion weighted imaging will be correlated to the golden standard\n           (computer tomography and MRI (T1 and STIR))."
        }, 
        "brief_title": "Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Body Weight", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with clinical and laboratory findings, highly suggestive for multiple\n             myeloma.\n\n        Exclusion Criteria:\n\n          -  All patients who are not allowed to be scanned on MRI (Pacemaker, implants ed.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "25 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with clinical and laboratory findings, highly suggestive for multiple myeloma.\n        All patients underwent bone marrow biopsy."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780766", 
            "org_study_id": "FIMM", 
            "secondary_id": "S51079"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Whole body MRI", 
            "Multiple myeloma", 
            "Diffusion Weighted MRI", 
            "Whole body scan"
        ], 
        "lastchanged_date": "January 28, 2013", 
        "location": {
            "contact": {
                "email": "steven.pans@uzleuven.be", 
                "last_name": "Steven Pans, MD", 
                "phone": "3216340505"
            }, 
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium"
                }, 
                "name": "University Hospitals Leuven"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "2", 
        "official_title": "Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI: What is the Added Value of Diffusion Weighted Imaging in Diagnosis and Follow-up", 
        "other_outcome": {
            "description": "correlation between early treatment response and outcome of the patient by measuring apparent diffusion coefficient", 
            "measure": "outcome", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "overall_contact": {
            "email": "steven.pans@uzleuven.be", 
            "last_name": "Steven Pans, MD", 
            "phone": "3216340505"
        }, 
        "overall_official": {
            "affiliation": "Universitaire Ziekenhuizen Leuven", 
            "last_name": "Steven Pans, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Validation of whole body MRI diffusion-weighted imaging in multiple myeloma at 3 Tesla MRI: correlation of the new MRI imaging technique (diffusion weighted imaging)to standard validated imaging technique (Computer Tomography and Magnetic Resonance Imaging)", 
            "measure": "Validation", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "reference": {
            "PMID": "22544292", 
            "citation": "Bannas P, Hentschel HB, Bley TA, Treszl A, Eulenburg C, Derlin T, Yamamura J, Adam G, St\u00fcbig T, Kr\u00f6ger N, Weber C. Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation. Eur Radiol. 2012 Sep;22(9):2007-12. doi: 10.1007/s00330-012-2445-y. Epub 2012 Apr 29."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780766"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universitaire Ziekenhuizen Leuven", 
            "investigator_full_name": "Steven Pans", 
            "investigator_title": "Medical Doctor Radiologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Whole body MRI with Diffusion weighted imaging is useful for treatment monitoring in multiple myeloma patients during and after therapy.\nMeasurement of apparent diffusion coefficient (ADC) and comparison of ADC before, during and after therapy. Correlation of ADC with clinical findings and standard MRI findings.", 
            "measure": "Therapy assessment", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "source": "Universitaire Ziekenhuizen Leuven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2008", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}